---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338009"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2026-08-06T20:10:58+00:00"
generated_at: "2026-08-06T20:14:25.164478+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CytomX Q2 2026 revenue $1.4M, cash $330.3M; Varseta-M registrational study planned for 1H 2027

## Summary
- Revenue $1.4M vs $18.7M YoY, driven by completion of BMS collaboration and lower Astellas activity.
- Cash, equivalents and investments $330.3M; plus $37M July Regeneron payment; runway to 2H 2028.
- Varseta-M Phase 1 data update expected end-2026; registrational study in CRC planned for 1H 2027.
- Regeneron collaboration expanded; $37M target selection payment received; potential milestones up to ~$4B.
- Board and leadership strengthened: Dr. Charles Fuchs, Mamata Gokhale, Alejandra Carvajal appointed.

## SEC filing metadata
- accession: 0001193125-26-338009
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2026-08-06T20:10:58+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/0001193125-26-338009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338009
- JSON: https://secwatch.observer/filing/0001193125-26-338009.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.